Skip to content
Open access

Status epilepticus in epileptic encephalopathy associated with TBC1D24 gene

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Case Presentation: A 19-year-old female patient from Porto Alegre, Rio Grande do Sul, was admitted to the emergency department with status epilepticus in July 2025. History of neuropsychomotor developmental delay in the context of genetic epileptic encephalopathy, confirmed by genetic testing performed at two different hospitals. The molecular epilepsy panel was performed in June 2021, identifying the trans pathogenic variant TBC1D24 in compound heterozygous state, besides other variants of uncertain significance. She has a biological brother with the same gene finding. During her hospitalization, she developed refractory and super-refractory states, with no response to maximum tolerated doses of cannabidiol, clobazam, diazepam, levetiracetam, lacosamide, lamotrigine, topiramate, and phenobarbital, and no suppression after weaning off intravenous anesthetics. He is intolerant to valproic acid, phenytoin and carbamazepine due to severe adverse reactions (drug-induced pancreatitis and impaired level of consciousness). He entered the trial EMERALD study for one week in September 2025 to use relutrigine, a selective sodium channel inhibitor, but withdrew from this medication after developing new status epilepticus during its use. She is currently presenting daily focal ocular seizures with misperception, intolerance to the ketogenic diet due to severe hypertriglyceridemia, dyskinetic oromasticatory movements probably due to chlorpromazine, and awaiting judicial approval for the insertion of a deep vagus nerve stimulator (VNS). Discussion: Epileptic encephalopathy related to a mutation in the TBC1D24 gene causes symptoms similar to those described in cases of Dravet syndrome (progressive focal myoclonic seizures, febrile, beginning in the first year of life, in addition to progression to status epilepticus), as well as impairment of neuropsychomotor development. Its management includes anti-seizure drugs and therapies for refractory epilepsy (e.g., cannabidiol, ketogenic diet, and neuromodulation devices). The complexity of the patient's epilepsy is due to its difficult control, as it involves a history of severe adverse reactions to medications, which extend to cannabidiol (hepatic intoxication) and the ketogenic diet (increased triglycerides with risk of pancreatitis). Final Comments: This case raises questions regarding the management of refractory epilepsy, as well as the structural limitations for its treatment within the Brazilian Unified Health System. This case opens up discussions about the treatment of refractory epilepsy, exploring the most significant options in the current scientific literature, whether or not they are available in Brazil, besides their limitations, adverse effects, and how to overcome them. Furthermore, it prompts reflection on the current scenario of managing these patients within the healthcare system and how to mitigate medical-legal difficulties in obtaining advanced therapies that have a major impact on the lives of these patients and their disease.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.